93 related articles for article (PubMed ID: 25105187)
1. Chronic granulomatous disease: a potentially lethal combination of immunodeficiency and excess inflammation.
Clin Infect Dis; 2014 Jul; 59(2):iii. PubMed ID: 25105187
[No Abstract] [Full Text] [Related]
2. Deficient autophagy unravels the ROS paradox in chronic granulomatous disease.
van de Veerdonk FL; Dinarello CA
Autophagy; 2014 Jun; 10(6):1141-2. PubMed ID: 24879159
[TBL] [Abstract][Full Text] [Related]
3. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans.
de Luca A; Smeekens SP; Casagrande A; Iannitti R; Conway KL; Gresnigt MS; Begun J; Plantinga TS; Joosten LA; van der Meer JW; Chamilos G; Netea MG; Xavier RJ; Dinarello CA; Romani L; van de Veerdonk FL
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3526-31. PubMed ID: 24550444
[TBL] [Abstract][Full Text] [Related]
4. Treatment With Anakinra, a Recombinant IL-1 Receptor Antagonist, Unlikely to Induce Lasting Remission in Patients With CGD Colitis.
Hahn KJ; Ho N; Yockey L; Kreuzberg S; Daub J; Rump A; Marciano BE; Quezado M; Malech HL; Holland SM; Heller T; Zerbe CS
Am J Gastroenterol; 2015 Jun; 110(6):938-9. PubMed ID: 26052777
[No Abstract] [Full Text] [Related]
5. Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab.
Campbell N; Chapdelaine H
J Allergy Clin Immunol Pract; 2017; 5(6):1748-1749. PubMed ID: 28919373
[No Abstract] [Full Text] [Related]
6. Anakinra for the inflammatory complications of chronic granulomatous disease.
van de Veerdonk FL; Netea MG; Dinarello CA; van der Meer JW
Neth J Med; 2011 Feb; 69(2):95. PubMed ID: 21411850
[No Abstract] [Full Text] [Related]
7. A case of macrophage activation syndrome developing in a patient with chronic granulomatous disease-associated colitis.
Akagi K; Kawai T; Watanabe N; Yokoyama M; Arai K; Harayama S; Oana S; Onodera M
J Pediatr Hematol Oncol; 2014 Apr; 36(3):e169-72. PubMed ID: 23652865
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide as a treatment for refractory CGD colitis.
Sokol H; Suarez F; Meatchi T; Malamut G; Pocidalo MA; Blanche S; Cellier C; Hermine O
Am J Gastroenterol; 2009 Apr; 104(4):1069. PubMed ID: 19293783
[No Abstract] [Full Text] [Related]
9. Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells.
Hönicke AS; Ender SA; Radons J
Int J Oncol; 2012 Aug; 41(2):753-8. PubMed ID: 22641358
[TBL] [Abstract][Full Text] [Related]
10. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan.
Harnack U; Johnen H; Pecher G
Anticancer Res; 2010 Oct; 30(10):3959-65. PubMed ID: 21036709
[TBL] [Abstract][Full Text] [Related]
11. Stool interleukin 1beta and interleukin 1 receptor antagonist concentrations in children with active ulcerative colitis and during recovery.
Wedrychowicz A; Stopyrowa J; Fyderek K; Miezynski W
Eur J Pediatr; 2003 Jul; 162(7-8):541-542. PubMed ID: 12719967
[No Abstract] [Full Text] [Related]
12. Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders.
Cantarini L; Lopalco G; Cattalini M; Vitale A; Galeazzi M; Rigante D
Isr Med Assoc J; 2015 Feb; 17(2):93-7. PubMed ID: 26223084
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.
Qian L; Xiang D; Zhang J; Zhu S; Gao J; Wang X; Gao J; Zhang Y; Shen J; Yu Y; Han W; Wu M
Biomed Pharmacother; 2013 Mar; 67(2):108-15. PubMed ID: 23433850
[TBL] [Abstract][Full Text] [Related]
14. Fever pitch.
Ledford H
Nature; 2007 Nov; 450(7170):600-1. PubMed ID: 18046368
[No Abstract] [Full Text] [Related]
15. Chronic granulomatous disease: recent advances in pathophysiology and treatment.
Seger RA
Neth J Med; 2010 Nov; 68(11):334-40. PubMed ID: 21116026
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease.
Gabrion A; Hmitou I; Moshous D; Neven B; Lefèvre-Utile A; Diana JS; Suarez F; Picard C; Blanche S; Fischer A; Cavazzana M; Touzot F
J Allergy Clin Immunol; 2017 May; 139(5):1641-1649.e6. PubMed ID: 27702670
[TBL] [Abstract][Full Text] [Related]
17. Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease.
Wang J; Mayer L; Cunningham-Rundles C
J Allergy Clin Immunol; 2005 May; 115(5):1092-4. PubMed ID: 15867874
[No Abstract] [Full Text] [Related]
18. [Polymorphism of the IL1RN gene in Spanish patients with ulcerative colitis].
González Sarmiento R; Araoz P; Rodríguez R; Oliveira A; Feranández Blanco I; Sánchez Rodríguez A
Med Clin (Barc); 1999 Jun; 112(20):778-9. PubMed ID: 10422059
[TBL] [Abstract][Full Text] [Related]
19. Long-acting antirheumatic drugs induce differentiation of cells of the monocyte-macrophage lineage and alter the expression of cytokines and IL-1 receptor antagonist.
Allison AC; Waters RV
Agents Actions Suppl; 1993; 44():113-27. PubMed ID: 8372721
[No Abstract] [Full Text] [Related]
20. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation.
Colville-Nash PR; Alam CA; Appleton I; Brown JR; Seed MP; Willoughby DA
J Pharmacol Exp Ther; 1995 Sep; 274(3):1463-72. PubMed ID: 7562523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
